Evaluating Laser Photobiomodulation for the Treatment of Neuropathic Pain in Chemotherapy-induced Peripheral Neuropathy in Cancer Patients

Exclusion Criteria

• •Patient unable to come twice a week to the Montpellier Cancer Institute;
• •Patient unable to sit for a 30-minutes period;
• •Patient with an open wound or ulcer on the treatment area;
• •Patient whose diagnosis of peripheral neuropathy is due to another cause (n.b., diabetes without neuropathy will not be a specific exclusion);
• •Patient with uncontrolled psychiatric illness or neurocognitive impairment that may interfere with assessments, as the investigator clinical discretion;
• •Patient whose estimated life expectancy is less than 3 months, as estimated by a clinical investigator;
• •Patient using another concurrent non-pharmacological intervention or complementary therapy for neuropathy during the study;
• •Patient who has been treated with CAPSAISINE during the previous 3 months;
• •Patient with pacemaker;
• •Epileptic patient;
• •Patient with photosensitive medications, or any medical condition causing sensitivity to light (n.b., Lupus);
• •Pregnant and/or breastfeeding woman;
• •Patient with primary tumor and/or metastases in areas to be treated by BPM (i.e., hands and/or feet);
• •Patient with pre-existing eye disease (such as maculopathy, glaucoma, cataract and retinal lesions), or a history of family eye diseases;
• •Patient who has been already been treated with photobiomodulation on the area of interest.
• •Participation in another concomitant clinical study with neuropathic pain or chemo-induced peripheral neuropathy as the primary endpoint.
• •Presence of a tattoo on the area to be treated.